Showing results (1001-1010 of 1,797) with videos related to

Sort By:
Pageof 180
Mabs|February 19, 2025
Targeting γc family cytokines with biologics: current status and future prospectsFabian Bick, Christophe Blanchetot, Bart N Lambrecht, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Mabs|August 28, 2024
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developabilityFortunato Ferrara, Adeline Fanni, Andre A R Teixeira, et al.
Mabs|December 8, 2022
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodiesAndrew Dippel, Austin Gallegos, Vineela Aleti, et al.
Mabs|November 23, 2022
A computational method for predicting the aggregation propensity of IgG1 and IgG4(P) mAbs in common storage buffersJames T Heads, Sebastian Kelm, Kerry Tyson, et al.
Mabs|November 27, 2019
Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosisThomas E Kraft, Wolfgang F Richter, Thomas Emrich, et al.
Mabs|November 29, 2019
Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequencesGargi Roy, Jason Reier, Andrew Garcia, et al.
Mabs|July 22, 2021
Targeting cancer with antibody-drug conjugates: Promises and challengesAlexis Q Dean, Shen Luo, Julianne D Twomey, et al.
Mabs|December 15, 2020
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipelineMarco Tuccori, Sara Ferraro, Irma Convertino, et al.
Mabs|July 27, 2021
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoVWen Jiang, Junchao Wang, Shasha Jiao, et al.
Pageof 180